Skip to main content

Table 4 Factor for correction of indirect (herd) effects

From: Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany

Age group

 

IPD

CAP

15 - 39

 

37,4%*

23.6%*

40 - 44

 

39.7%*

23.6%*

45 - 49

 

39.7%*

16,2%*

50 - 64

 

17.5%*

16,2%*

65+

 

37.9%*

14.3%*

  1. *Adjusted according to Claes et al. for German serotype coverage based on IPD data from Pilishvili et al. and CAP data from Ray et al. [34].
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us